2-methoxyestradiol has been researched along with Metastase in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gorska, M; Kuban-Jankowska, A; Wozniak, M; Wyszkowska, RM | 1 |
| Arnott, J; Hahn, NM; Hammers, H; Harrison, MR; Kim, K; Liu, G; Oh, WK; Perlman, S; Pili, R; Sidor, C; Sweeney, C; Wilding, G | 1 |
| James, J; Miller, KD; Murry, DJ; Sidor, C; Sledge, GW; Storniolo, AM; Treston, AM | 1 |
| Kataoka, M; Mukhopadhyay, T; Roth, JA; Schumacher, G | 1 |
| Green, SJ; Gubish, ER; Lavallee, TM; Pribluda, VS; Swartz, GM; Treston, A | 1 |
1 review(s) available for 2-methoxyestradiol and Metastase
| Article | Year |
|---|---|
2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate.
Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Animals; Cell Division; Cell Line; Estradiol; Humans; Neoplasm Metastasis; Neoplasms; Neoplasms, Experimental; Neovascularization, Pathologic; Neovascularization, Physiologic; Tumor Cells, Cultured | 2000 |
2 trial(s) available for 2-methoxyestradiol and Metastase
| Article | Year |
|---|---|
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).
Topics: 2-Methoxyestradiol; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Estradiol; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Nanoparticles; Neoplasm Metastasis; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Treatment Outcome | 2011 |
Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer.
Topics: 2-Methoxyestradiol; Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Estradiol; Fatigue; Female; Half-Life; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome; Tubulin Modulators; Urinalysis; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2007 |
2 other study(ies) available for 2-methoxyestradiol and Metastase
| Article | Year |
|---|---|
Impact of Apparent Antagonism of Estrogen Receptor β by Fulvestrant on Anticancer Activity of 2-Methoxyestradiol.
Topics: 2-Methoxyestradiol; Antineoplastic Agents, Hormonal; Apoptosis; Bone Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Gene Expression Regulation, Neoplastic; Histones; Humans; Neoplasm Metastasis; Neoplasm Proteins; Osteosarcoma; Phosphorylation; Protein Processing, Post-Translational | 2016 |
Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines.
Topics: 2-Methoxyestradiol; Animals; Antineoplastic Agents; Apoptosis; Cell Division; Disease Models, Animal; DNA Fragmentation; Dose-Response Relationship, Drug; Estradiol; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Tumor Cells, Cultured | 1999 |